Title
Safety and Efficacy of Herbmed Plus in Patients withRenal Calculi
A Phase II, 28 Week, Randomized, Double- Blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 'Herbmed Plus' an Ayurvedic Formulation in Patients With Renal Calculi
Phase
Phase 2Lead Sponsor
Amai Charitable TrustStudy Type
InterventionalStatus
Unknown statusIndication/Condition
RENAL CALCULIIntervention/Treatment
herbmed plus ...Study Participants
84More specifically, the present invention relates to a 'Herbal Preparation' that is useful for
Treatment of Renal calculi
Reduction in the stone size & surface area
The expulsion of stone
Decreased need of Analgesic(Antiinflammatory Effect)
Stops the recurrence and reformation of renal
Study duration 28 weeks
No. of Scheduled visits 8 visits
Study product Dose, Group one-:1capsule (of 500 mg) orally twice a day with meals for 24 weeks. Group two-:placebo1capsule (of 500 mg) orally twice a day with meals for 24 weeks.
500 mg Twice day for 6 month with lunch and dinner.
Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
Inclusion Criteria: Age 10-75 years (Both inclusive) Patients with Renal calculi, diagnosis confirmed by plain X-ray KUB &/or ultrasound KUB/CT scan Abdomen Size of the calculi ranging from 04 mm -09 mm Able and willing to give written informed consent and comply with the requirements of the study protocol Patients of reproductive potential (males and females) and willing to use a reliable means of contraception (e.g hormonal contraceptive patch, intrauterine device and physical barrier) throughout study participation Patients will to cooperate & give consent for the trial& comes for regular follow up. Exclusion Criteria: Patients having acute condition of renal calculi. Any systemic disease requiring other medications of surgery for calculus condition. Complicated cases of Renal Calculi requiring surgical condition. Chronic or current infectious disease such as but not limited to chronic renal infection including active urinary tract infection.Uncontrolled diabetes, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction Any other urogenital disorders. Liver dysfunction, defined as total bilirubin more then 1.5 the upper limit of Normal, aspartate aminotransferase more then 2.5 upper limit of Normal, or alanine aminotransferase more then 2.5 upper limit of Normal, Kidney disease, including serum creatinine level more then 1.5 upper limit of Normal, Subjects on herbal supplements for stone disease (plant extracts preparations or herbal medicines etc.) within previous 3 months. Participated in another clinical drug trial within 3 months before recruitment. Pregnancy or breast feeding Evidence of significant uncontrolled concomitant disease which in the Investigator's opinion would preclude patient participation Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline Patients with psychiatric illness or other condition that would limit compliance with study requirements Patients receiving or has received any investigational drug within 30 days before receiving the first dose of study medication Subjects who refuse to sign the informed consent document .
